Marijuana Rescheduled Medical Impact | Business and Finance News

The DEA just reclassified marijuana from Schedule One to Schedule Three, unlocking major tax benefits for medical cannabis businesses by allowing deductions under Section 280E—though it adds compliance headaches. Big players like Canopy Growth and Tilray face mixed impacts: Canopy USA, its U.S. affiliate, will see gains, while Tilray’s U.S. focus leans toward beverages. Green Thumb Industries remains unclear due to lack of sales breakdowns. While this is a crucial win for medical cannabis, the road ahead is complex, with regulatory hurdles and opposition looming. Recreational cannabis rescheduling remains a distant goal, but public sentiment is shifting—slowly, but surely. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/116f017d06d991a6